NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 301–400 of 1,000
Koeberle, A., Muñóz, E., Appendino, G., Minassi, A., Pace, S., Rossi, A., Weinigel, C., Barz, D., Sautebin, L., Caprioglio, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500308c · Cited by 68
Rizvi, F., Shukla, S., & Kakkar, P. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.118 · Cited by 67
“Increased basal activation of Nrf2, as has been observed in genetic analyses ofmany human tumors, allows the cancer cell to avoid the adverse effects of high levels of ROS and hence evade apoptosis.(46) In view of the loss of PHLPP2 function in many cancers, our investigation, which unveils a salient aspect of surviva…”
BackgroundKim, E. H., Baek, S. H., Shin, D., Lee, J., & Roh, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5498908 · Cited by 66
“Nrf2 is constantly degraded by the proteosomal activity of Keap1; therefore, Nrf2 activity is upregulated by Keap1 inhibition [22, 23].”
BackgroundNanotherapeutics interfere with cellular redox homeostasis for highly improved photodynamic therapy
Qian, C., Yu, W., Ye, J., Liu, M., Liu, W., Zhang, C., Zhang, C., Feng, J. X., & Zhang, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119500 · Cited by 67
Effect of ultraviolet radiation on the Nrf2 signaling pathway in skin cells
Ryšavá, A., Vostálová, J., & Svobodová, A. R. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1962566 · Cited by 74
“Thus, impaired Nrf2 activity promotes tumor proliferation and metastasis resulting in a worse prognosis (Sporn and Liby 2012; Xue et al. 2020).”
BackgroundLi, F., Lv, Z., Zhang, X., Dong, Y., Ding, X., Li, Z., Li, S., Yao, C., & Yang, D. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202111900 · Cited by 67
Eisenstein, A. S., Hilliard, B. K., Pope, S. D., Zhang, C., Taskar, P., Waizman, D. A., Israni-Winger, K., Tian, H., Luan, H. H., & Wang, A. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.015 · Cited by 73
Sigma 1 receptor: A novel therapeutic target in retinal disease
Smith, S. B., Wang, J., Cui, X., Mysona, B. A., Zhao, J., & Bollinger, K. E. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.07.003 · Cited by 66
“NRF2 is considered a “master regulator” of the antioxidant gene response as it modulates transcription of more than 500 antioxidant and cytoprotective genes (Sporn and Liby, 2012; Gorrini et al., 2013).”
BackgroundPharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
Telkoparan‐Akillilar, P., Süzen, S., & Saso, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082025 · Cited by 69
“Therefore, it is debatable whether the activation, or the inhibition, of Nrf2 is beneficial for the prevention or treatment of cancer [116].”
BackgroundLi, J., Wang, Q., Yang, Y., Lei, C., Yang, F., Liang, L., Chen, C., Xia, J. L., Wang, K., & Tang, N. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1459-6 · Cited by 70
The Links between Parkinson’s Disease and Cancer
Ejma, M., Madetko‐Alster, N., Brzecka, A., Gurański, K., Alster, P., Misiuk‐Hojło, M., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. (2020) · Biomedicines · doi:10.3390/biomedicines8100416 · Cited by 73
Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
Duong, H., Yi, Y. W., Kang, H. J., Hong, Y. B., TANG, W., Wang, A., Seong, Y., & Bae, I. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2229 · Cited by 68
“NRF2, by inducing expression of multiple genes that have roles in oxidative stress, detoxification, drug resistance and cell survival, functions either as a tumor protector or oncogene (27-30).”
The see-saw of Keap1-Nrf2 pathway in cancer
Pandey, P., Singh, A. K., Singh, M., Tewari, M., Shukla, H. S., & Gambhir, I. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.006 · Cited by 71
Fatal Alliance of Hypoxia-/HIF-1α-Driven Microenvironmental Traits Promoting Cancer Progression
Vaupel, P. W., & Multhoff, G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34461-0_21 · Cited by 74
Functional Role of NRF2 in Cervical Carcinogenesis
Ma, J., Hatila, T., Jiao, S.-J., Jian-He, Z., Jing-Bao, X., & Hasim, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133876 · Cited by 65
To, C., Ringelberg, C. S., Royce, D. B., Williams, C. R., Risingsong, R., Sporn, M. B., & Liby, K. T. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv061 · Cited by 63
“Although both agents activate the Nrf2 pathway, whether such enhanced Nrf2 activity is advantageous or disadvantageous with respect to human cancer is known to depend on context (9), and the complexity of the microarray results further complicates the overall benefit versus risk analysis.”
BackgroundSelf-citationRising levels of atmospheric oxygen and evolution of Nrf2
Gacesa, R., Dunlap, W. C., Barlow, D. J., Laskowski, R. A., & Long, P. F. (2016) · Scientific Reports · doi:10.1038/srep27740 · Cited by 64
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 70
“Previous studies have shown that constitutively active Nrf2 pathway, due to loss of Keap1 (Kelch-like erythroid-derived Cap-n-Collar Homology (ECH)-associated protein-1), results in acute kidney injury, chronic kidney disease, cancer [183,184], and activation of Phase II enzymes [185].”
BackgroundWater transport proteins-aquaporins (AQPs) in cancer biology
Dajani, S., Saripalli, A., & Sharma-Walia, N. (2018) · Oncotarget · doi:10.18632/oncotarget.26351 · Cited by 70
“In cancer the activation of nuclear factor (erythroid-derived 2)- like 2 (NRF2) increases the transcriptional response of antioxidant proteins [79].”
BackgroundYumimoto, K., Yamauchi, Y., & Nakayama, K. I. (2020) · Cancers · doi:10.3390/cancers12051249 · Cited by 72
“Exposure of cells to oxidative or electrophilic stress, however, results in the direct modification of highly reactive thiols in KEAP1 and consequent inactivation of CRL3KEAP1 and stabilization of NRF2 followed by its translocation to the nucleus, where it induces the expression of a battery of cytoprotective genes [2…”
BackgroundThe prospect of precision therapy for renal cell carcinoma
Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D. Y. C., Tortora, G., & Massari, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.003 · Cited by 71
Ma, T., Lan, D.-H., He, S.-Z., Ye, Z., Li, P., Zhai, W., Chen, W.-Q., Huang, Y. X. R., Fu, Y., Sun, A., et al. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.01.018 · Cited by 65
“In nucleus, Nrf2 regulates transcriptional activation of antioxidant genes through binding to ARE (antioxidant response elements) (Liu et al., 2017; Sporn and Liby, 2012).”
BackgroundIntermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer
Kang, H. S., Kwon, H. Y., Kim, I. K., Ban, W. H., Kim, S. W., Kang, H. H., Yeo, C. D., & Lee, S. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-58906-7 · Cited by 67
Zhang, Y., Xu, Y., Lu, W., Li, J., Yu, S., Brown, E. J., Stanger, B. Z., Rabinowitz, J. D., & Yang, X. (2022) · Science Advances · doi:10.1126/sciadv.abo0404 · Cited by 80
“In response to oxidative stress, nuclear factor–erythroid 2 p45-related factor-2 (NRF2), a master regulator of cellular redox response ( 31 ), stimulates the expression of a wide range of antioxidant and detoxification genes, including G6PD ( 32 ).”
InfluentialNew developments in mechanisms of prostate cancer progression
Howard, N., Clementino, M., Kim, D., Wang, L., Verma, A., Shi, X., Zhang, Z., & DiPaola, R. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.003 · Cited by 64
Yu, Y., Li, Z., Cao, G., Huang, S., & Yang, H. (2019) · Journal of Food Science · doi:10.1111/1750-3841.14609 · Cited by 63
Shan, K., Feng, N., Zhu, D., Qu, H., Fu, G., Li, J., Cui, J., Chen, H., Wang, R., Qi, Y., et al. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02940-w · Cited by 66
Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis
Sun, Q., Zeng, Y., Qin, Y., Fan, G., Ji, S., Zhuo, Q., Xu, W., Liu, W., Hu, Q., Liu, M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01452-3 · Cited by 69
Expected and Unexpected Effects of Pharmacological Antioxidants
Tyuryaeva, I. I., & Lyublinskaya, O. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119303 · Cited by 76
Arfmann-Knübel, S., Struck, B., Genrich, G., Helm, O., Sipos, B., Sebens, S., & Schäfer, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132978 · Cited by 70
Understanding the role of NRF2-regulated miRNAs in human malignancies
Shah, N., Rushworth, S. A., Murray, M. Y., Bowles, K. M., & MacEwan, D. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1181 · Cited by 66
“Conversely, an ‘oncomiR’ is an miRNA that targets directly tumor suppressor mRNA expression. miR-21, for example, is up-regulated in a range of malignancies; including solid tumors, CLL, AML, and multiple myeloma (MM); through targeting the classic tumor suppressor PTEN [23, 25].”
BackgroundInfluentialMatschke, J., Riffkin, H., Klein, D., Handrick, R., Lüdemann, L., Metzen, E., Shlomi, T., Stuschke, M., & Jendrossek, V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6589 · Cited by 68
“Generally, cancer cells increase expression of antioxidant proteins by activation of the transcription factors nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (63) or FoxO transcription factors (17, 27).”
Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors
Thiel, G., & Rößler, O. G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.029 · Cited by 66
Xu, X., Yang, Y., Liu, X., Cao, N., Zhang, P., Zhao, S., Chen, D., Li, L., He, Y., Dong, X., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0885 · Cited by 67
Wang, X., & Hai, C. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.012 · Cited by 65
Progress and Prospects of Reactive Oxygen Species in Metal Carcinogenesis
Wang, L., Wise, J. T. F., Zhang, Z., & Shi, X. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0061-2 · Cited by 60
“Enhancement of inducible Nrf2 activity, which lessens oxidative or mutagenic stress, appears to be beneficial during pre-malignant states [34, 35].”
Yang, F., Li, J., Deng, H., Wang, Y., Lei, C., Wang, Q., Jin, X., Liang, L., Xia, J. L., Pan, X., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019101964 · Cited by 59
“Abbreviations: DEN, diethylnitrosamine; CCl 4 , carbon tetrachloride; Phe, phenylalanine; PPP, picropodophyllin; Bru, brusatol; H&E, hematoxylin – eosin; N, non-tumor; (Sporn & Liby, 2012).”
Zhang, M., Liu, J., Yu, Y., Liu, X., Shang, X., Du, Z., Xu, M., & Zhang, T. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c00523 · Cited by 68
Li, X., Liang, M., Jiang, J., He, R., Wang, M., Guo, X., Shen, M., & Qin, R. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.26776 · Cited by 58
“Additionally, aberrant Nrf2 overexpression has been observed in several human cancers, and constitutive Nrf2 activation protects cancer cells against oxidative stress and contributes to the chemo-resistance [25, 26].”
BackgroundArumugam, T., Pillay, Y., Ghazi, T., Nagiah, S., Abdul, N. S., & Chuturgoon, A. A. (2018) · Mycotoxin Research · doi:10.1007/s12550-018-0335-0 · Cited by 68
Diehl, K., Dinges, L.-A., Helm, O., Ammar, N., Plundrich, D., Arlt, A., Röcken, C., Sebens, S., & Schäfer, H. (2018) · Oncogene · doi:10.1038/onc.2017.299 · Cited by 58
Patel, U. N., Patel, U. D., Khadayata, A. V., Vaja, R. K., Patel, H. B., & Modi, C. M. (2021) · Water Air & Soil Pollution · doi:10.1007/s11270-021-05274-1 · Cited by 61
Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival
Qian, Z., Zhou, T., Gurguis, C. I., Xu, X., Wen, Q., Lv, J., Fang, F., Hecker, L., Cress, A. E., Natarajan, V., et al. (2015) · Scientific Reports · doi:10.1038/srep16889 · Cited by 58
TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin
Moruno-Manchon, J. F., Uzor, N.-E., Kesler, S. R., Wefel, J. S., Townley, D. M., Nagaraja, A. S., Pradeep, S., Mangala, L. S., Sood, A. K., & Tsvetkov, A. S. (2016) · Aging · doi:10.18632/aging.101144 · Cited by 64
“Since Nrf2, an obvious choice, also strongly upregulates a number of anti-oxidant genes that are cytoprotective for cancer cells [46], we searched for another neuroprotective candidate.”
Pan-urologic cancer genomic subtypes that transcend tissue of origin
Chen, F., Zhang, Y., Bossé, D., Lalani, A. A., Hakimi, A. A., Hsieh, J. J.-D., Choueiri, T. K., Gibbons, D. L., Ittmann, M., & Creighton, C. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00289-x · Cited by 62
SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1–Nrf2
Burgener-Gasser, A.-V., Bantug, G. R., Meyer, B. J., Higgins, R., Ghosh, A., Bignucolo, O., Ma, E. H., Loeliger, J., Unterstab, G., Geigges, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0482-2 · Cited by 57
Sun, Y., Xu, L., Zheng, D., Wang, J., Liu, G., Mo, Z., Liu, C., Zhang, W., Yu, J., Xing, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102793 · Cited by 54
Chan, T. K., Tan, W. S. D., Peh, H. Y., & Wong, W. S. F. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600657 · Cited by 55
“Nrf2 is a key regulatory transcription factor that induces antioxidant genes to protect against the deleterious effects of ROS (19).”
BackgroundZhang, J., Li, X., Wei, J., Chen, H., Lu, Y., Li, L., Han, L., & Lu, C. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.09.048 · Cited by 55
Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?
van der Wijst, M. G. P., Brown, R., & Rots, M. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.004 · Cited by 60
Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance
Chun, K., Kim, D., & Surh, Y. (2021) · Cells · doi:10.3390/cells10040758 · Cited by 60
“It has been speculated that sustained accumulation or activation of Nrf2 confers upon a subset of premalignant or cancerous cells an advantageous environment for proliferation and metastasis by evading apoptosis and resisting therapeutic intervention [15].”
BackgroundAntagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 59
Zheng, K., Sheng, Z.-Q., Li, Y., & Lu, H.-H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.072 · Cited by 55
Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target
Ma, S., Paiboonrungruan, C., Yan, T., Williams, K. P., Major, M. B., & Chen, X. L. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13681 · Cited by 57
“Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway
Best, S. A., & Sutherland, K. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1496756 · Cited by 54
“Comprehensive genomic sequencing studies have reported deregulation of the KEAP1-NRF2 pathway in human cancer, through both genetic and epigenetic mechanisms (reviewed in [17,18]).”
BackgroundLeung, H.-W., Lau, E. Y.-T., Leung, C. O. N., Lei, M. M. L., Mok, E. H. K., Ma, V. W. S., Cho, W. C. S., Ng, I. O., Yun, J., Cai, S., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.008 · Cited by 59
Targeting the Redox Landscape in Cancer Therapy
Narayanan, D., Ma, S., & Özcelik, D. (2020) · Cancers · doi:10.3390/cancers12071706 · Cited by 61
“On the other hand, Nrf2 plays a protective role and prevents cancer development by reducing ROS levels [172,173].”
InfluentialHuang, S., He, T., Yang, S., Sheng, H., Tang, X., Bao, F., Wang, Y., Lin, X., Yu, W., Cheng, F., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1072 · Cited by 54
“Notably, mutagenic ROS is involved during carcinogenesis and chemotherapy resistance (15).”
The Role of KEAP1-NRF2 System in Atopic Dermatitis and Psoriasis
Ogawa, T., & Ishitsuka, Y. (2022) · Antioxidants · doi:10.3390/antiox11071397 · Cited by 58
“However, NRF2 has controversial roles in cancer [55]; that is, NRF2 may be protective in the early stages of cancer but may be tumorigenic in the advanced stages (i.”
BackgroundSulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm
Ullah, M. (2015) · Medicines · doi:10.3390/medicines2030141 · Cited by 66
“The transcription faction NRF2 (nuclear factor erythroid 2-related factor 2) is the principal regulator of the expression of molecules with antioxidant functions within the cell [22].”
BackgroundThe Involvement ofNRF2in Lung Cancer
Bauer, A. K., Hill, T., & Alexander, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/746432 · Cited by 59
“By the nature of its cellular functions of alleviating oxidative stress, NRF2 is important in the prevention of disease onset and progression and has established a definitive role in cancer prevention [10, 12, 13, 18].”
BackgroundInfluentialNrf2 Modulates Host Defense during Streptococcus pneumoniae Pneumonia in Mice
Gomez, J. C., Dang, H., Martin, J. R., & Doerschuk, C. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600043 · Cited by 53
“cancer and other diseases suggest that Nrf2 is a doubled-edged sword (23, 24).”
Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present)
Zhou, H.-S., Wang, Y., You, Q., & Jiang, Z. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1715365 · Cited by 55
Payandeh, Z., Tazehkand, A. P., Barati, G., Pouremamali, F., Kahroba, H., Baradaran, B., & Samadi, N. (2020) · Biochimie · doi:10.1016/j.biochi.2020.09.014 · Cited by 55
Nrf2, the Major Regulator of the Cellular Oxidative Stress Response, is Partially Disordered
Karunatilleke, N. C., Fast, C. S., Ngo, V., Brickenden, A. M., Duennwald, M. L., Konermann, L., & Choy, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147434 · Cited by 55
“Aberrant activation of Nrf2 has been shown to play a pivotal role in pathogenesis and chemoresistance for many types of cancer [18,62].”
BackgroundJiang, Z., Chu, H., Xi, M., Yang, T., Jia, J.-M., Huang, J., Guo, X., Zhang, X., You, Q., & Sun, H.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075076 · Cited by 52
“While another Keap1 substrate, Nrf2, has been known as an attractive target for chemprevention of cancer [59].”
BackgroundWang, J., Zhao, J., Cui, X., Mysona, B. A., Navneet, S., SAUL, A. B., Ahuja, M., Lambert, N. A., Gazaryan, I. G., Thomas, B., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.02.001 · Cited by 55
“The basic leucine zipper transcription factor, NRF2, regulates transcription of more than 500 antioxidant and cytoprotective genes [26-29].”
BackgroundRole of Autophagy in Renal Cancer
Cao, Q., & Bai, P. (2019) · Journal of Cancer · doi:10.7150/jca.29285 · Cited by 53
FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding
Cheng, K., Lin, R., Cheng, J., Wang, S., Yu, J., Wu, J., Liang, Y., Hsu, H.-M., Yu, J., & Yu, A. L.-T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.022 · Cited by 52
“The effector function of Nrf2 may contribute to chemotherapy resistance by several mechanisms: 1) suppression of oxidative stress, which is an important aspect of the cytotoxicity of chemotherapy; 2) drug detoxification by glutathione and other conjugating mechanisms; 3) transcriptional up-regulation of the multidrug…”
BackgroundLagoa, R., Marques‐da‐Silva, D., Diniz, M., Daglia, M., & Bishayee, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.002 · Cited by 57
Bacterial Infections Affect Male Fertility: A Focus on the Oxidative Stress-Autophagy Axis
Wang, S., Zhang, K., Yao, Y., Li, J., & Deng, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727812 · Cited by 62
“N. gonorrhoeae can attach to the spermatozoa by its pili and then infects other tissues through triggers a flow of polymorphonuclear leukocytes (Stohl et al., 2012).”
BackgroundPPIA dictates NRF2 stability to promote lung cancer progression
Lü, W., Cui, J., Wang, W., Hu, Q., Xue, Y., Liu, X., Gong, T., Lu, Y., Ma, H., Yang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48364-4 · Cited by 60
“NRF2 protein in thecellwastightly controlled byubiquitinproteasomalpathway 42 .”
AKR1C enzymes sustain therapy resistance in paediatric T-ALL
Bortolozzi, R., Bresolin, S., Rampazzo, E., Paganin, M., Maule, F., Mariotto, E., Boso, D., Minuzzo, S. A., Agnusdei, V., Viola, G., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0014-0 · Cited by 56
MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis
Cosentino, G., Plantamura, I., Cataldo, A., & Iorio, M. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205143 · Cited by 55
“Therefore, it is not unusual to find contradictory literature concerning the prospective of using NRF2 inhibitors for therapeutic purposes [49,50].”
BackgroundNrf2: a main responsive element in cells to mycotoxin-induced toxicity
Kozieł, M. J., Kowalska, K., & Piastowska‐Ciesielska, A. W. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-02995-4 · Cited by 55
“The role of Nrf2 in cells is twofold: on the one hand, it protects cells against ROS and decreases DNA damage caused by it, but on the other hand, prolonged expression of this factor is associated with a more aggressive and resistant type of cancers and may be oncogenic (Sporn and Liby 2012).”
BackgroundNRF2 mediates melanoma addiction to GCDH by modulating apoptotic signalling
Verma, S. K., Crawford, D., Khateb, A., Feng, Y., Sergienko, E. A., Pathria, G., Ma, C.-T., Olson, S. H., Scott, D. A., Murad, R., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00985-x · Cited by 54
Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer
Goruppi, S., & Dotto, G. P. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.08.006 · Cited by 56
Resveratrol-loaded Nanoparticles Induce Antioxidant Activity against Oxidative Stress
Kim, J.-H., Park, E.-Y., Ha, H., Jo, C.-M., Lee, S. S., Lee, S. S., & Kim, J. W. (2015) · Asian-Australasian Journal of Animal Sciences · doi:10.5713/ajas.15.0774 · Cited by 57
Kaulmann, A., Legay, S., Schneider, Y., Hoffmann, L., & Bohn, T. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500947 · Cited by 53
Genetic mutations associated with lung cancer metastasis to the brain
Aljohani, H. M., Aittaleb, M., Furgason, J. M., Amaya, P., Deeb, A., Chalmers, J. J., & Bahassi, E. M. (2018) · Mutagenesis · doi:10.1093/mutage/gey003 · Cited by 57
Li, Y., Li, G.-H., Zhou, M., Xiang, L., Ren, D., Lou, H., Wang, X., & Shen, T. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.09.010 · Cited by 54
Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors
Alexandrova, E., Salvati, A., Pecoraro, G., Lamberti, J., Melone, V., Sellitto, A., Rizzo, F. M., Giurato, G., Tarallo, R., Nassa, G., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.864612 · Cited by 56
Xu, L., Zhu, J., Xu, X., Zhu, J., Li, L., Xi, M., Jiang, Z., Zhang, M.-Y., Liu, F., Lu, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00170 · Cited by 51
Stress response pathways, toxicity pathways and adverse outcome pathways
Jennings, P. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0974-4 · Cited by 54
Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3848 · Cited by 49
“NRF2 stabilization is associated with poor prognosis (13 – 20), resistance to chemo-and radiotherapy (21, 22), cancer cell survival (22), proliferation (23), metabolic reprogramming (20, 24 – 26), and metastasis (27).”
The promising antioxidant effects of lignans: Nrf2 activation comes into view
Hassanein, E. H. M., Althagafy, H. S., Baraka, M. A., Abd‐alhameed, E. K., Ibrahim, I. M., El‐Maksoud, M. S. A., Mohamed, N. M., & Ross, S. A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03102-x · Cited by 64
“Thus, it plays a critical role in regulating the production of antioxidants within cells (Moi et al. 1994; Sporn and Liby 2012).”
BackgroundSchiavoni, V., Emanuelli, M., Milanese, G., Galosi, A. B., Pompei, V., Salvolini, E., & Campagna, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413239 · Cited by 52
Lim, J., Lee, S. H., Cho, S., Lee, I., Kang, B. Y., & Choi, H. J. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0123-9 · Cited by 49
Velavan, B., Divya, T., Anandasadagopan, S. K., & Sudhandiran, G. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.105 · Cited by 51
Badea, M. A., Prodana, M., Dinischiotu, A., Crihana, C., Ioniță, D., & Balaș, M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040228 · Cited by 50
“Moreover, a significant down-regulation of poly-ubiquitinated Nrf2 expression was noticed in cells exposed to MWCNT-COOH-CDDP suggesting the activation of Nrf2 by its translocation to the nucleus [66].”
BackgroundInfluentialLei, K., Xia, Y., Wang, X., Ahn, E. H., Jin, L., & Ye, K. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101578 · Cited by 53
“Under resting conditions, Nrf2 is constitutively degraded by the Kelch-like ECH-associated protein 1 (KEAP1)-Cullin 3 (CUL3) E3 ligase complex [55].”
Möhler, H., Pfirrmann, R. W., & Frei, K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2566 · Cited by 49
“Their basal ROS levels are low and their anti-oxidant capacity is robust due to the activation of Nrf2, the master regulator of anti-oxidant responses which includes the induction of anti-oxidant enzymes such as catalase or glutathione-S-transferase (3,5,7).”
BackgroundInfluentialDama, E., Melocchi, V., Dezi, F., Pirroni, S., Carletti, R. M., Brambilla, D., Bertalot, G., Casiraghi, M., Maisonneuve, P., Barberis, M. C. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3005 · Cited by 49
Yasuda, D., Nakajima, M., Yuasa, A., Obata, R., Takahashi, K., Ohe, T., Ichimura, Y., Komatsu, M., Yamamoto, M. P., Imamura, R. M., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.083 · Cited by 51
Guo, H. W., Adah, D., James, P., Liu, Q., Guo-zheng, L., Ahmadu, P. U., Chai, L., Wang, S., Liu, Y., & Hu, L. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2523-x · Cited by 50
Quarter-Century Explorations of Bioactive Polyphenols: Diverse Health Benefits
Chu, A. J. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704134 · Cited by 52
“(a) Nrf2 is a conserved master regulator of cellular antioxidant responses [18,19].”
BackgroundRolfs, F., Huber, M., Kuehne, A., Kramer, S., Haertel, E., Muzumdar, S., Wagner, J., Tanner, Y., Böhm, F., Smola, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0614 · Cited by 47
Guo, H. W., Li, M.-J., Liu, Q.-Q., Guo, L., Ma, M., Wang, S., Yu, B., & Hu, L. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1384-1 · Cited by 49
“Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a basic leucine-zipper transcription factor that binds antioxidant response elements (AREs), plays an important role in preventing development of oxidative stress through upregulation of the Nrf2-related antioxidants [4].”
Choi, S. H., Kim, B., Robinson, J., Fink, S. P., Yan, M., Sporn, M. B., Markowitz, S. D., & Letterio, J. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69672 · Cited by 52
Self-citationZheng, K., Zhang, Q., Lin, G., Li, Y., Sheng, Z.-Q., Wang, J., Chen, L., & Lu, H.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.14785 · Cited by 47
“Transcription of these genes, including heme oxygenase-1 (HO1), NADPH quinone oxidoreductase 1 (NQO1) and glutamate cysteine ligase catalytic subunit (GCLC), could significantly inhibit ROS production and oxidative stress [14].”
Background
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.